Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer

被引:16
|
作者
Wada, Miku [1 ]
Kukita, Asako [1 ]
Sone, Kenbun [1 ]
Hamamoto, Ryuji [2 ,3 ]
Kaneko, Syuzo [2 ]
Komatsu, Masaaki [2 ,3 ]
Takahashi, Yu [1 ]
Inoue, Futaba [1 ]
Kojima, Machiko [1 ]
Honjoh, Harunori [1 ]
Taguchi, Ayumi [1 ]
Kashiyama, Tomoko [1 ]
Miyamoto, Yuichiro [1 ]
Tanikawa, Michihiro [1 ]
Tsuruga, Tetsushi [1 ]
Mori-Uchino, Mayuyo [1 ]
Wada-Hiraike, Osamu [1 ]
Osuga, Yutaka [1 ]
Fujii, Tomoyuki [1 ]
机构
[1] Univ Tokyo, Dept Obstet & Gynecol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[2] Natl Canc Ctr, Div Mol Modificat & Canc Biol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] RIKEN Ctr Adv Intelligence Project, Canc Translat Res Team, Chuo Ku, 1-4-1 Nihonbashi, Tokyo 1030027, Japan
关键词
epigenetic modifier; histone methyltransferase; SETD8; high-grade serous ovarian cancer; UNC0379; HISTONE; METHYLATION; P53; ACTIVATION; EXPRESSION;
D O I
10.3390/biom10121686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The histone methyltransferase SETD8, which methylates the lysine 20 of histone H4 (H4K20), is reportedly involved in human carcinogenesis along with nonhistone proteins such as p53. However, its expression profiles and functions in the context of high-grade serous ovarian carcinoma (HGSOC) are still unknown. The purpose of this study was to investigate the role of SETD8 in HGSOC. We performed quantitative real-time PCR and immunohistochemistry to detect the expression of SETD8 in HGSOC samples and normal ovarian specimens. Then, we assessed the effect of the inhibition of SETD8 expression using small interfering RNA (siRNA) and a selective inhibitor (UNC0379) on cell proliferation and apoptosis in HGSOC cells. The expression of SETD8 was significantly upregulated in clinical ovarian cancer specimens compared to that in the corresponding normal ovary. In addition, suppression of SETD8 expression in HGSOC cells with either siRNA or UNC0379 resulted in reduced levels of H4K20 monomethylation, inhibition of cell proliferation, and induction of apoptosis. Furthermore, UNC0379 showed a long-term antitumor effect against HGSOC cells, as demonstrated by colony-formation assays. SETD8 thus constitutes a promising therapeutic target for HGSOC, warranting further functional studies.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [1] Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
    Matthews, Bayley G.
    Bowden, Nikola A.
    Wong-Brown, Michelle W.
    CANCERS, 2021, 13 (23)
  • [2] Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer
    Ivan, Cristina
    Hu, Wei
    Bottsford-Miller, Justin
    Zand, Behrouz
    Dalton, Heather J.
    Liu, Tao
    Huang, Jie
    Nick, Alpa M.
    Lopez-Berestein, Gabriel
    Coleman, Robert L.
    Baggerly, Keith A.
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2013, 128 (03) : 506 - 511
  • [3] KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
    De Donato, Marta
    Babini, Gabriele
    Mozzetti, Simona
    Buttarelli, Marianna
    Ciucci, Alessandra
    Arduini, Gloria
    De Rosa, Maria Cristina
    Scambia, Giovanni
    Gallo, Daniela
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [4] High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
    Lisio, Michael-Antony
    Fu, Lili
    Goyeneche, Alicia
    Gao, Zu-hua
    Telleria, Carlos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (04)
  • [5] Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics
    Konishi, Ikuo
    Abiko, Kaoru
    Hayashi, Takuma
    Yamanoi, Koji
    Murakami, Ryusuke
    Yamaguchi, Ken
    Hamanishi, Junzo
    Baba, Tsukasa
    Matsumura, Noriomi
    Mandai, Masaki
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 33 (05)
  • [6] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
  • [7] Drugs Repurposing in High-Grade Serous Ovarian Cancer
    Torralba, Manuel
    Farra, Rossella
    Maddaloni, Marianna
    Grassi, Mario
    Dapas, Barbara
    Grassi, Gabriele
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (42) : 7222 - 7233
  • [8] Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion
    Tang, Jessica
    Pulliam, Nicholas
    Oezes, Ali
    Buechlein, Aaron
    Ding, Ning
    Keer, Harold
    Rusch, Doug
    O'Hagan, Heather
    Stack, M. Sharon
    Nephew, Kenneth P.
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 1226 - 1240
  • [9] Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
    Zaid, Tarrik M.
    Yeung, Tsz-Lun
    Thompson, Melissa S.
    Leung, Cecilia S.
    Harding, Tom
    Co, Ngai-Na
    Schmandt, Rosie S.
    Kwan, Suet-Ying
    Rodriguez-Aguay, Cristian
    Lopez-Berestein, Gabriel
    Sood, Anil K.
    Wong, Kwong-Kwok
    Birrer, Michael J.
    Mok, Samuel C.
    CLINICAL CANCER RESEARCH, 2013, 19 (04) : 809 - 820
  • [10] CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma
    Mei, Jie
    Tian, Huixiang
    Huang, Hsuan-Shun
    Wu, Nayiyuan
    Liou, Yu-Ligh
    Chu, Tang-Yuan
    Wang, Jing
    Zhang, Wei
    CELL CYCLE, 2023, 22 (01) : 85 - 99